Latest Blogs

Feb 14, 2019
It's hard enough to try dating again after a cancer diagnosis and treatment, but some of my patients also face strong opposition from their adult children.
Feb 14, 2019
Dr. Suneel D. Kamath was surprised to learn how important laughter and levity can be in the physician-patient relationship.
Feb 11, 2019
When a patient asks, "Why me?", Dr. Stephanie Graff considers that they may not be asking for a list of their cancer risk factors.
Feb 07, 2019
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Subscribe to this column

George W. Sledge, MD, FASCO

George W. Sledge, Jr., MD, FASCO, is Chief of the Division of Oncology and Professor of Medicine at Stanford University School of Medicine. Prior to joining Stanford, he was Co-Director of the Breast Cancer Program as well as the Ballve-Lantero Professor of Oncology and Professor of Medicine and Pathology at the Indiana University Simon Cancer Center. He was the 2010-2011 President of ASCO, and he has served on numerous ASCO committees. He has also served as Chair of the Breast Committee of the Eastern Cooperative Oncology Group from 2002-2009. Dr. Sledge is currently a member of the Measures Task Force, as well as the Quality of Care and CancerLinQ Patient Reported Outcomes Committees. He received the 2006 Komen Foundation Brinker Award for Scientific Distinction in 2006, The Breast Cancer Research Foundation Jill Rose Award, and the William L. McGuire Award from the San Antonio Breast Cancer Symposium in 2010.

May 25, 2011
I have been working on my Presidential Address in recent weeks, an address that I wanted to end by looking back to the moral center of our profession. In doing so I came across Francisco Goya’s Self-...
May 20, 2011
The last few weeks before the Annual Meeting are an increasingly frenzied period for ASCO staff and for your president. Orchestrating the meeting of 30,000 oncology professionals requires a great deal of work by staff.  There is also, inevitably, some last minute reshuffling of the scientific...
May 13, 2011
In a previous blog, I discussed “Hill Day,” the annual pilgrimage that your ASCO volunteers make to our nation's Capitol in support of federal cancer research funds. Hill Day was...
May 09, 2011
One of the more astonishing and unexpected developments of the past two decades has been the expansion of the clinical cancer research universe from a relatively few countries (the U.S., Canada, Western Europe, Japan, and Australia, to be precise) to an essentially global enterprise. This expansion...
May 09, 2011
Many thought the budget battle was over after Congress struck a deal in April to fund the government through the end of fiscal year 2011. The cancer community collectively breathed a sigh of relief when the numbers came out and the National Institutes of Health (NIH) received only a 0.8% reduction...
May 08, 2011
Two articles in the most recent New England Journal of Medicine should get you thinking about where we are as a profession.  Both have to do with prostate cancer, and while unrelated in their subject matter they both require us to address the same issue:  whom do we treat?